Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

O. Knyazev1, N. Fadeeva*2, A. Kagramanova1, P. Shcherbakov3, I. Ruchkina1, A. Parfenov1, A. Konoplyannikov4

1Moscow Clinical Research Centre, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Moscow Clinical Research Centre, Department of Inflammatory bowel disease, Moscow, Russian Federation, 3Central Research Institute of Gastroenterology, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 4Medical Radiological Scientific Centre, Department of Stem Cells Therapy, Obninsk, Russian Federation

P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Ward*1, 2, L. Beswick2, P. Thwaites1, J. Hogg1, G. Rosella3, J. Reynolds4, D. Van Langenberg2, P. Gibson1, 3, M. Sparrow1, 3

1Alfred Hospital, Gastroenterology, Melbourne, Australia, 2Eastern Health, Gastroenterology, Melbourne, Australia, 3Monash University, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia, 4Monash University, Biostatistics, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia

P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisationECCO '16 Amsterdam
Year: 2016
Authors:

W. K. van Deen*1, M. Skup2, A. Centeno1, N. Duran1, P. Lacey1, D. Jatulis3, E. Esrailian1, M. G. van Oijen4, D.W. Hommes1

1UCLA Centre for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, California, United States, 2AbbVie, US Immunology, North Chicago, Illinois, United States, 3Anthem Blue Cross, California, Woodland Hills, California, United States, 4Academic Medical Centre, Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands

P488: IBS-type symptoms in patients with quiescent inflammatory bowel disease are unrelated to ongoing inflammationECCO '16 Amsterdam
Year: 2016
Authors:

D. Hoekman*1, J. Zeevenhooven2, G. D’Haens3, M. Benninga1

1Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, 3Academic Medical Centre (AMC), Department of Gastroenterology,

P489: Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.ECCO '16 Amsterdam
Year: 2016
Authors:

M. Meglicka*1, M. Szczepanski2, M. Dadalski2, J. Kierkus2

1The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 2The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P490: Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

B. Jackson*, D. Con, P. De Cruz

Austin Health, Gastroenterology, Melbourne, Australia

P491: In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.ECCO '16 Amsterdam
Year: 2016
Authors:

O. Nomura*, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, S. Watanabe

Juntendo University, Department of Gastroenterology, Tokyo, Japan

P492: Perioperative complications have long-term effect on quality of life after restorative proctocolectomyECCO '16 Amsterdam
Year: 2016
Authors:

Y. Lee1, A. McCombie*1, 2, R. Vanamala1, R. Gearry3, F. Frizelle1, E. McKay1, J. Williman4, T. Eglinton1

1University of Otago, Department of Surgery, Christchurch, New Zealand, 2University of Otago, Department of Medicine, Dunedin, New Zealand, 3University of Otago, Department of Medicine, Christchurch, New Zealand, 4University of Otago, Christchurch, Department of Population Health, Christchurch, New Zealand

P493: Prevalence and risk factors for postoperative septic complications in Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Guasch1, 2, A. Clos1, M. Manyosa3, T. Lobatón3, J. R. Gómez2, M. Piñol4, E. Cabré3, J. Troya4, E. Domènech*3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 2Hospital San Jorge, Digestive Surgery, Huesca, Spain, 3Hospital Germans Trias i Pujol. CIBEREHD, Gastroenterology, Badalona, Spain, 4Hospital Universitari Germans Trias i Pujol, Digestive Surgery, Badalona, Spain

P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

AOU Careggi, Regional Referral Centre of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experienceECCO '16 Amsterdam
Year: 2016
Authors:

M. Bortlik*1, 2, M. Kolar1, D. Duricova1, 3, K. Malickova4, V. Hruba1, N. Machkova1, K. Mitrova1, M. Lukas1, M. Lukas1, 4

1Iscare, IBD Clinical and Research Centre, Prague, Czech Republic, 2First Medical Faculty and Central Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, 3First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, 4First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysisECCO '16 Amsterdam
Year: 2016
Authors:

E. J. Louis*1, R. Löfberg2, W. Reinisch3, D. Schwartz4, J.-F. Maa5, S. Berg5, B. Huang5, A. W. Wang5, A. M. Robinson5, B. Pappalardo5

1University of Liège and CHU, Liège, Belgium, 2Karolinska Institutet and IBD Unit, Sophiahemmet, Stockholm, Sweden, 3Medical University of Vienna, Vienna, Austria, 4Vanderbilt University Medical Centre, Nashville, United States, 5AbbVie Inc., North Chicago, Illinois, United States

P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general populationECCO '16 Amsterdam
Year: 2016
Authors:

J. Kim*1, J. P. Im1, J.-J. Yim2, C. K. Lee3, D. I. Park4, C. S. Eun5, S.-A. Jung6, J.E. Shin7, K.-M. Lee8, J. H. Cheon9

1Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 2Seoul National University College of Medicine, Department of Internal Medicine and Lung Institute, Seoul, South Korea, 3Kyung Hee University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 4Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 5Hanyang University, Department of Internal Medicine, Guri, South Korea, 6Ewha Woman’s University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 7Dankook University College of Medicine, Department of Internal Medicine, Cheonan, South Korea, 8The Catholic University of Korea College of Medicine, Department of Internal Medicine, Seoul, South Korea, 9Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea

P498: Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapyECCO '16 Amsterdam
Year: 2016
Authors:

T. Engel*1, G. Ben-Haim2, N. Levhar1, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Gastroenterology, Ramat Gan, Israel, 2Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Internal Medicine C, Ramat Gan, Israel

P499: Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from KoreaECCO '16 Amsterdam
Year: 2016
Authors:

H. Seo*1, S. H. Park1, K. Chang1, G.-U. Kim1, E. M. Song1, M. Seo1, H.-S. Lee2, S.W. Hwang1, D.-H. Yang1, B. D. Ye1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1

1Asan Medical Centre, University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, South Korea, 2Asan Medical Centre, University of Ulsan College of Medicine, Health Screening and Promotion Centre, Seoul, South Korea

P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA studyECCO '16 Amsterdam
Year: 2016
Authors:

E. Seidman*1, U. Kopylov2, C.-Y. Chao1, M. Girardin3, M. Starr4

1Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada, 2Sheba Medical Centre, Gastroenterology, Tel Hashomer, Tel Aviv, Israel, 3University Hospital of Geneva, Department of Gastroenterology and Hepatology, Geneva, Switzerland, 4Research Institute of the McGill University Health Centre, Rheumatology, Montreal, Canada

P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulationECCO '16 Amsterdam
Year: 2016
Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

1Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom, 2Imperial College, Nutrition and Dietetic Research Group, Faculty of Medicine, London, United Kingdom, 3Chelsea and Westminster Hospital NHS Foundation Trust, Department of Paediatric Gastroenterology, London, United Kingdom

P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implicationsECCO '16 Amsterdam
Year: 2016
Authors:

x. Cortés*1, J. R. MOLÉS2, S. Fernández3, J. Clofent3, M. Moreno4, J. Rodriguez3, J. Primo3

1Hospital de Sagunto, Valencia, Spain, 2HOSPITAL DE SAGUNTO, VALENCIA, Spain, 3HOSPITAL DE SAGUNTO, Valencia, Spain, 4Hospital de sagunto, Valencia, Spain

P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational studyECCO '16 Amsterdam
Year: 2016
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P504: Stability observations in tacrolimus suppositoriesECCO '16 Amsterdam
Year: 2016
Authors:

M. Lie*1, E. Jansen2, P. Hoeben2, R. Zaal3, D. Hodes2, M. Rosman2, W. Loos2, J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2TioFarma BV, Oud-Beijerland, Netherlands, 3Erasmus Medical Centre, Hospital Pharmacy, Rotterdam, Netherlands